2023-09-08 22:00:00
The competitive tender procedure of the Global Fund to Fight AIDS, Tuberculosis and Malaria, implemented with its partners and generic drug manufacturers, will make it possible to offer first-line anti-HIV treatment ( TLD: composed of dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) “for less than 45 dollars (…) per person per year, a price lower than ever”, explains the Global Fund. This 25% price reduction will enable governments in countries with limited resources to expand access to essential HIV services. The World Health Organization (WHO) has recommended TLD as “preferential first-line treatment for HIV in adults and adolescents since 2018. This medication is recommended because it quickly suppresses the virus, presents less side effects and that it is easy to administer. In a statement, Peter Sands, Executive Director of the Global Fund, explains that “The countries most affected by HIV face severe budgetary constraints, while millions of HIV-positive people do not have access to treatment. quality. With the TLD price reduction, governments and other entities responsible for implementing Global Fund grants will be able to expand their treatment programs and invest more in prevention, saving more lives and reducing the number of new ones. infections. “. This announcement at the end of August is a continuation of the progress made in 2017, when Indian generic drug manufacturers had succeeded, through licensing contracts and with the support of UNAIDS, Unitaid, and the American Pepfar program. , the Bill & Melinda Gates Foundation, the Global Fund and other partners, to offer the TLD to low- and middle-income countries at a ceiling price of approximately $75 per person per year. At the time, this unprecedented award already represented a major breakthrough in the global availability of high-quality, highly effective HIV treatment. Since then, through global partnerships and country-led initiatives, some 19 million people living with HIV in resource-limited settings have been able to receive TLD, according to the Clinton Health Access Initiative. In its press release, the Global Fund explains that “these large volumes are inseparable from the gains in production efficiency and the lasting drop in prices obtained today; countries will be better equipped than ever to help all people living with HIV requiring TLD. In addition to facilitating access to health products internationally, the Global Fund “encourages the production of health products close to the people and communities it supports, in collaboration with partner organizations, such as Unitaid, Pepfar, WHO and other organizations that support the development of local and regional manufacturing.
1694225492
#Global #Fund #cheaper #TLD
